GT199900158A - "combinaciones para la diabetes" - Google Patents

"combinaciones para la diabetes"

Info

Publication number
GT199900158A
GT199900158A GT199900158A GT199900158A GT199900158A GT 199900158 A GT199900158 A GT 199900158A GT 199900158 A GT199900158 A GT 199900158A GT 199900158 A GT199900158 A GT 199900158A GT 199900158 A GT199900158 A GT 199900158A
Authority
GT
Guatemala
Prior art keywords
combinations
diabetes
antidiabètic
agent
sulfonilurea
Prior art date
Application number
GT199900158A
Other languages
English (en)
Inventor
Randall W Whitcomb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT199900158A publication Critical patent/GT199900158A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

LA INVENCIÒN SE REFIERE A LAS COMBINACIONES DE UN AGENTE ANTIDIABÈTICO DE GLITAZONA Y UN AGENTE ANTIDIABÈTICO DE BIGUANIDINA, Y OPTATIVAMENTE UN AGENTE ANTIDIABÈTICO DE SULFONILUREA (LAS FÒRMULAS CORRESPONDIENTES SE OBSERVAN ABAJO) , SON ÙTILES PARA TRATAR LA DIABÈTES MELLITUS Y MEJORAR EL CONTROL GLUCÈMICO.
GT199900158A 1998-11-09 1999-09-17 "combinaciones para la diabetes" GT199900158A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/189,132 US6011049A (en) 1997-02-19 1998-11-09 Combinations for diabetes

Publications (1)

Publication Number Publication Date
GT199900158A true GT199900158A (es) 2001-03-10

Family

ID=22696072

Family Applications (1)

Application Number Title Priority Date Filing Date
GT199900158A GT199900158A (es) 1998-11-09 1999-09-17 "combinaciones para la diabetes"

Country Status (20)

Country Link
US (1) US6011049A (es)
EP (2) EP1514550A3 (es)
JP (1) JP2002529417A (es)
AR (1) AR020973A1 (es)
AT (1) ATE293980T1 (es)
AU (1) AU5347399A (es)
CA (1) CA2345524C (es)
CO (1) CO5150152A1 (es)
CR (1) CR6128A (es)
DE (1) DE69925019T2 (es)
DK (1) DK1128834T3 (es)
ES (1) ES2241305T3 (es)
GT (1) GT199900158A (es)
HN (1) HN1999000184A (es)
PA (1) PA8484901A1 (es)
PE (1) PE20001235A1 (es)
PT (1) PT1128834E (es)
SI (1) SI1128834T1 (es)
UY (1) UY25791A1 (es)
WO (1) WO2000027401A1 (es)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
AU6452098A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
DE69910045T2 (de) 1998-09-09 2004-04-22 Metabasis Therapeutics Inc., San Diego Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US6878749B2 (en) 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
CN1516705A (zh) 2000-03-08 2004-07-28 ֢�����ƹ�˾ 新的芳基果糖-1,6-二磷酸酶抑制剂
US6610272B1 (en) * 2000-05-01 2003-08-26 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6780432B1 (en) * 2000-05-01 2004-08-24 Aeropharm Technology, Inc. Core formulation
US6296874B1 (en) * 2000-05-01 2001-10-02 Aeropharm Technology Incorporated Core formulation comprising troglitazone and abiguanide
AU5745601A (en) * 2000-05-01 2001-11-12 Aeropharm Technology Inc A core formulation
JP2004510716A (ja) * 2000-10-02 2004-04-08 ユーエスヴイ　リミテッド メトフォルミン含有持続性放出薬理組成物とその製造方法
US6866866B1 (en) * 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
CA2434169C (en) 2001-01-12 2011-03-15 Sun Pharmaceutical Industries Limited Spaced drug delivery system
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
FR2823225B1 (fr) * 2001-04-04 2004-09-17 Pierre Desreumaux Utilisation de composes modulant l'activite de l'heterodimere rxr-ppar a titre de medicament pour le traitement de l'hepatite c, et procede de criblage correspondant
CA2443632C (en) * 2001-04-10 2011-05-03 Sun Pharmaceutical Industries Limited Timed pulse release composition
US20040156903A1 (en) * 2002-05-22 2004-08-12 Abrams Andrew L.. Metering and packaging of controlled release medication
SE0101980D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
SE0101982D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
AU2001273290B2 (en) * 2001-07-10 2004-10-07 Kos Life Sciences, Inc. Core formulation comprising troglitazone and a biguanide
AU2001273289B2 (en) * 2001-07-10 2004-10-07 Kos Life Sciences, Inc. Core formulation comprising pioglitazone hydrochloride and a biguanide
MXPA04000176A (es) * 2001-07-10 2004-10-27 Kos Life Sciences Inc Formulacion de nucleo.
CA2452558C (en) 2001-07-17 2009-12-22 N-Gene Research Laboratories Inc. A synergistic pharmaceutical combination for the prevention or treatment of diabetes
US20040170714A1 (en) * 2001-07-27 2004-09-02 Herwig Buchholz Bauhinia extracts
WO2003011308A1 (fr) * 2001-07-30 2003-02-13 Mitsubishi Pharma Corporation Medicaments destines a l'amelioration de l'hyperglycemie post-prandiale
FR2832633B1 (fr) * 2001-11-28 2004-09-24 Lipha Composition pharmaceutique comprenant une association metformine et un acide 4-oxo-butanoique et son utilisation pour traiter le diabete
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
FR2834640B1 (fr) * 2002-01-11 2004-09-24 Lipha Composition pharmaceutique comprenant une glitazone et un acide 4-oxobutanoique et son utilisation pour traiter le diabete
WO2003061643A1 (es) * 2002-01-25 2003-07-31 Laboratorios Silanes, S.A. De C.V. Composicion farmaceutica para el control de la glucosa en sangre de pacientes con diabetes tipo 2
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
PL376577A1 (pl) 2002-06-17 2006-01-09 Themis Laboratories Private Limited Wielowarstwowe tabletki zawierające tiazolidinedion i biguanidy oraz metody ich wytwarzania
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US8821915B2 (en) * 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7959946B2 (en) * 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
JP4694841B2 (ja) 2002-09-20 2011-06-08 アンドルックス ラボズ リミテッド ライアビリティ カンパニー ビグアニドおよびチアゾリジンジオン誘導体を含有する多段階製剤
BR0314655A (pt) * 2002-09-26 2005-08-02 Eisai Co Ltd Droga de combinação
IN192749B (es) * 2002-11-15 2004-05-15 Ranbaxy Lab Ltd
WO2004108067A2 (en) * 2003-04-03 2004-12-16 Sun Pharmaceutical Industries Limited Programmed drug delivery system
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
ATE457166T1 (de) * 2003-07-24 2010-02-15 Wockhardt Ltd Orale zusammensetzungen zur behandlung von diabetes
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
RU2359661C2 (ru) 2003-10-31 2009-06-27 Такеда Фармасьютикал Компани Лимитед Твердый препарат
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
JP2008517921A (ja) * 2004-10-25 2008-05-29 ノバルティス アクチエンゲゼルシャフト Ｄｐｐ−ｉｖ阻害剤、ｐｐａｒ抗糖尿病薬およびメトホルミンの組合わせ剤
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
WO2006074278A2 (en) * 2005-01-05 2006-07-13 Mitsunori Ono Compositions for treating diabetes or obesity
WO2007011524A1 (en) * 2005-07-14 2007-01-25 Franco Folli Daily dosage regimen for treating diabetes, obsity, metabolic syndrome and polycystic ovary syndrome
MXPA05009633A (es) * 2005-09-08 2007-03-07 Silanes Sa De Cv Lab Composicion farmaceutica estable de glimepirida de liberacion inmediata y metformina de liberacion prolongada.
MXPA05010977A (es) * 2005-10-12 2007-04-11 Abdala Leopoldo Espinosa Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus.
MXPA05014092A (es) * 2005-12-20 2007-06-20 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias derivadas de la tiazolidinedionas combinadas con una biguanida para su uso en diabetes mellitus tipo 2.
FR2896159B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
WO2007127791A2 (en) * 2006-04-25 2007-11-08 The Administrators Of The Tulane Educational Fund New pharmacological method for treatment of neuropathic pain
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
EA015687B1 (ru) 2006-05-04 2011-10-31 Бёрингер Ингельхайм Интернациональ Гмбх Полиморфы
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US20090221703A1 (en) 2006-07-09 2009-09-03 Chongxi Yu High penetration composition and uses thereof
US20090238763A1 (en) 2006-07-09 2009-09-24 Chongxi Yu High penetration compositions and uses thereof
TW200816995A (en) * 2006-08-31 2008-04-16 Daiichi Sankyo Co Ltd Pharmaceutical composition containing insulin sensitizers
EP2781505A1 (en) 2006-10-02 2014-09-24 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of prostaglandins and related compounds with very high skin penetration rates
WO2008056207A1 (en) 2006-11-08 2008-05-15 Chongxi Yu Transdermal delivery systems of peptides and related compounds
JP5324463B2 (ja) 2006-12-10 2013-10-23 チョンシー ユー β−ラクタム抗生物質の経皮送達システム
CA2674822C (en) 2007-01-15 2017-08-01 Chongxi Yu Positively charged water-soluble prodrugs of retinoids and retinoid-like compounds with very high skin penetration rates
EP3176169A1 (en) 2007-01-31 2017-06-07 Chongxi Yu Positively charged water-soluble prodrugs of 1h-imidazo[4,5-c]quinolin-4-amines and related compounds with very high skin penetration rates
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
US20080064701A1 (en) * 2007-04-24 2008-03-13 Ramesh Sesha Anti-diabetic combinations
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
CN105250285B (zh) * 2007-04-11 2019-09-06 奥默罗斯公司 预防和治疗成瘾的组合物和方法
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
KR20150058566A (ko) * 2007-06-04 2015-05-28 테크필즈 인크 매우 높은 피부 및 막 침투율을 가지는 ｎｓａｉａ 약물전구체 및 이들의 새로운 의약적 용도
CA2696579C (en) * 2007-08-17 2017-01-24 Boehringer Ingelheim International Gmbh Purine derivatives for use in the treatment of fab-related diseases
US8551524B2 (en) * 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
WO2010011860A1 (en) * 2008-07-23 2010-01-28 Diabetomics, Llc Methods for detecting pre-diabetes and diabetes
UY32030A (es) * 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
EP2326326B1 (en) * 2008-08-15 2019-10-09 Boehringer Ingelheim International GmbH Dpp-4 inhibitors for use for the treatment of wound healing in diabetic patients
WO2010028211A1 (en) * 2008-09-04 2010-03-11 Rozmanith Anthony I Health care
US20100075937A1 (en) * 2008-09-24 2010-03-25 Hollis-Eden Pharmaceuticals, Inc. Patient populations and treatment methods
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN108191846B (zh) * 2008-12-04 2021-08-20 于崇曦 高穿透性组合物及其应用
TWI508965B (zh) 2008-12-23 2015-11-21 Boehringer Ingelheim Int 有機化合物的鹽形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
CN106692144A (zh) 2009-03-11 2017-05-24 奥默罗斯公司 预防和治疗成瘾的组合物和方法
WO2010127099A2 (en) 2009-04-29 2010-11-04 Amarin Corporation Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
KR101343249B1 (ko) 2009-04-29 2013-12-19 아마린 파마, 인크. 안정한 제약 조성물 및 그의 사용 방법
KR101784528B1 (ko) 2009-05-08 2017-10-12 테크필즈 바이오켐 코., 엘티디. 펩티드 및 펩티드­관련 화합물의 고침투성 전구약물 조성물
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
US9969751B2 (en) 2009-06-10 2018-05-15 Techfields Pharma Co., Ltd. High penetration prodrug compositions of antimicrobials and antimicrobial-related compounds
CN108096237A (zh) 2009-06-15 2018-06-01 阿马里纳制药公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
US20110065756A1 (en) * 2009-09-17 2011-03-17 De Taeye Bart M Methods and compositions for treatment of obesity-related diseases
ES2760917T3 (es) 2009-11-27 2020-05-18 Boehringer Ingelheim Int Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina
BR112012026005A2 (pt) * 2010-04-13 2015-09-08 Nucitec Sa De Cv composições e métodos para tratar diabetes do tipo ii e distúrbios relacionados
PT2566469T (pt) 2010-05-05 2023-01-10 Boehringer Ingelheim Int Terapia de combinação
AU2011257964B2 (en) 2010-05-24 2014-10-30 Ozstar Therapeutics Pty Ltd Anti-diabetic compositions and methods
EP2585101A1 (en) 2010-06-24 2013-05-01 Boehringer Ingelheim International GmbH Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
WO2012074930A2 (en) 2010-11-29 2012-06-07 Amarin Pharma, Inc. Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
PL2731947T3 (pl) 2011-07-15 2019-07-31 Boehringer Ingelheim International Gmbh Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
CN103159651B (zh) * 2011-12-14 2015-06-17 安徽贝克联合制药有限公司 磺酰脲胍及其制备方法和用途
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
MX2014013910A (es) 2012-05-16 2015-06-04 Techfields Pharma Co Ltd Composiciones de profarmacos de alta penetracion y composiciones farmaceuticas de los mismos para el tratamiento de afecciones pulmonares.
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
NL2015957B1 (en) 2015-12-14 2017-06-29 Scala Pharma B V Compositions and methods for inducing beige or brown fat tissue.
EP3184106A1 (en) 2015-12-23 2017-06-28 Sanofi-Aventis Deutschland GmbH Growth differentiation factor 15 as biomarker for metformin
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
CN111991386A (zh) 2018-09-24 2020-11-27 阿马里纳药物爱尔兰有限公司 降低受试者的心血管事件的风险的方法
NL2024493B1 (en) 2019-12-16 2021-09-02 Logick Energetics B V Pharmaceutical composition for preventing or stopping metastases
WO2021125951A1 (en) 2019-12-18 2021-06-24 Logick Energetics B.V. Pharmaceutical composition for use in preventing or stopping metastases
NL2025335B1 (en) 2020-04-10 2021-10-26 Logick Energetics B V Pharmaceutical composition for treatment of corona virus infection
NL2028476B1 (en) 2021-06-17 2022-12-27 Logick Energetics B V Pharmaceutical composition for increasing mitochondrial activity and/or improving adiponectin production
NL2029634B1 (en) 2021-11-04 2023-06-02 Logick Energetics B V Pharmaceutical composition for increasing mitochondrial activity and/or improving adiponectin production

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
CA2180296C (en) * 1995-07-03 2007-01-09 Yoshio Tsujita Treatment of arteriosclerosis and xanthoma
GB9715295D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment

Also Published As

Publication number Publication date
UY25791A1 (es) 2001-03-16
JP2002529417A (ja) 2002-09-10
EP1128834B1 (en) 2005-04-27
US6011049A (en) 2000-01-04
ATE293980T1 (de) 2005-05-15
PT1128834E (pt) 2005-07-29
DK1128834T3 (da) 2005-07-04
DE69925019D1 (de) 2005-06-02
ES2241305T3 (es) 2005-10-16
EP1514550A2 (en) 2005-03-16
CR6128A (es) 2000-11-30
EP1128834A1 (en) 2001-09-05
AR020973A1 (es) 2002-06-05
AU5347399A (en) 2000-05-29
CA2345524A1 (en) 2000-05-18
PE20001235A1 (es) 2000-11-08
EP1514550A3 (en) 2009-04-29
PA8484901A1 (es) 2000-09-29
SI1128834T1 (es) 2005-08-31
WO2000027401A1 (en) 2000-05-18
CO5150152A1 (es) 2002-04-29
HN1999000184A (es) 2000-02-10
DE69925019T2 (de) 2006-03-02
CA2345524C (en) 2005-09-20

Similar Documents

Publication Publication Date Title
GT199900158A (es) "combinaciones para la diabetes"
ES2195970T3 (es) L-ribavirina y usos de la misma.
MY126559A (en) Fungicidal 2-methoxybenzophenones
BG103591A (en) Pesticide 1-arylpyrazols
GT199900055A (es) Nuevas dihidropirimidinas2 heterocìclicamente sustituidas.
AR010062A1 (es) Nuevos benzamidaldehidos y su utilizacion
DZ2569A1 (fr) Dérivés 1,2,3,4-tétrahydronaphtalène substitués.
ES2179273T3 (es) N-bencil-2-fenilindolas como agentes estrogenicos.
HRP20030472B1 (en) Methanesulphonamido-benzofuran, preparation method and use thereof as synthesis intermediate
DE69803907T2 (de) Fungizide 2-Methoxybenzophenone
ECSP034600A (es) Compuestos de lactama
ES2158327T3 (es) Derivados de benzo(g)quinolina.
ATE76069T1 (de) 5-nitrobenzo(de>isochinolin-1,3-dione, ihre herstellung und verwendung.
RS50071B (sr) Novi oblik soli pantoprazola
ES2190164T3 (es) Compuestos piretroides y composiciones que los contienen para controlar plagas.
EA200100347A1 (ru) Метод и композиция для лечения и профилактики туберкулеза
IT1302243B1 (it) Sintesi dell'1,1,1,3,3-pentafluoropropano.
AR008860A1 (es) Empleo de 1-hidroxi-2-piridonas para el tratamiento de la dermatitis seborreica
DE60006825D1 (de) Serotonerge benzofurane
ATE250021T1 (de) Hydroxycyclopentanone
ATE259379T1 (de) Fluoresceinisothiocyanat-(fitc)-sinistrin, seine herstellung und verwendung
TR199901017A2 (xx) B�cek ilac� terkibi.
DK1073447T3 (da) N1-modificerede glycopeptider
ATE251457T1 (de) Substituierte 1,2,3,4-tetrahydro-2- dibenzofuranamine und 2- aminocyclohepta(b)benzofurane
ES2166045T3 (es) Procedimiento para la preparacion de compuestos de 4,6-bis(ariloxi)pirimidina asimetricos.